Pharma

Showing of 1 - 20 from 191 results
Pharma - Total results - 191
DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines
India

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines

Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."

Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down
Business

Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down

Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses

Earnings of Sensex companies to decline up to 8% this year on economic concerns; fiscal stimulus may help recovery: Analyst
Business

Earnings of Sensex companies to decline up to 8% this year on economic concerns; fiscal stimulus may help recovery: Analyst

At present, Indian indices are under-performing as compared to others and a package from the government can help cover the ground, he said.

Glenmark to study potential COVID-19 drug combination; to look to enroll 158 hospitalised patients
Business

Glenmark to study potential COVID-19 drug combination; to look to enroll 158 hospitalised patients

On 1 May, Glenmark Pharmaceuticals said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.

Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag
Business

Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag

Sensex tumbled 260 points on Friday, dragged by losses in banking and financial stocks as RBI's rate cut and other measures to prop up the economy failed to meet market expectations.

Markets close day's session on buoyant note: Sensex up 622 points, Nifty above 9,050-mark; HDFC top gainer, surges over 5%
Business

Markets close day's session on buoyant note: Sensex up 622 points, Nifty above 9,050-mark; HDFC top gainer, surges over 5%

The Sensex settled 622.44 points or 2.06 percent higher at 30,818.61, while the NSE Nifty rose 187.45 points, or 2.11 percent, to end at 9,066.55

Market ends on positive note; Sensex jumps 637 points, Nifty above 9,350; Re settles higher at Rs 75.46 against dollar
Business

Market ends on positive note; Sensex jumps 637 points, Nifty above 9,350; Re settles higher at Rs 75.46 against dollar

The Nifty bank index was up by 4 percent. Besides, sharp buying was also witnessed in the auto and metal stocks.

Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir
Business

Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir

Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19

Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir
Business

Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir

Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19

Markets close on positive note: Sensex 199 points up, propelled by strong gains in RIL; rupee closes higher
Business

Markets close on positive note: Sensex 199 points up, propelled by strong gains in RIL; rupee closes higher

Reliance Industries was the biggest contributor to the gains on the index, jumping over 3 percent after the company announced that US-based PE firm Vista Equity Partners will buy 2.32 percent stake in Jio Platforms for Rs 11,367 crore.

Sensex ends over 260 points lower at 31,454; Nifty falls 87.90 points to 9,206; except energy, infra, all sectoral indices in red
Business

Sensex ends over 260 points lower at 31,454; Nifty falls 87.90 points to 9,206; except energy, infra, all sectoral indices in red

The Sensex surrendered all its early gains to end 262 points lower on Tuesday due to emergence of a sudden sell-off in financial stocks at the fag-end of the sessio

Lupin gets inspection closure report from USFDA for Pithampur manufacturing plant in Madhya Pradesh
Business

Lupin gets inspection closure report from USFDA for Pithampur manufacturing plant in Madhya Pradesh

Drug maker Lupin on Thursday said the US health regulator has closed the inspection of its manufacturing facility in Pithampur, Madhya Pradesh

Coronavirus outbreak highlighted vulnerabilities in medical manufacturing supply chain: Fitch Solutions
Business

Coronavirus outbreak highlighted vulnerabilities in medical manufacturing supply chain: Fitch Solutions

With pharmaceutical supply chains under immense pressure due to COVID-19, China's role as a global ingredient producer has come under scrutiny, Fitch Solutions has said

Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru
Business

Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru

Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., said on Thursday it has received the Establishment Inspection Report (EIR) from the USFDA (the United States Food and Drug Administration) for the pre-approval inspection at two of its biologics manufacturing facilities in Bengaluru

Lupin's Mandideep Unit II facility in Madhya Pradesh receives EIR from USFDA
Business

Lupin's Mandideep Unit II facility in Madhya Pradesh receives EIR from USFDA

Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh

Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Business

Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites

Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur

Coronavirus Outbreak: Which sectors will bounce back, which will take time post-lockdown, experts weigh in
Business

Coronavirus Outbreak: Which sectors will bounce back, which will take time post-lockdown, experts weigh in

Sectors that depend on people's behaviour would take the longest time to recover after the end of the lockdown period, while those curbed by the government to contain the spread of coronavirus are set for a bounce-back immediately after the restrictions are removed, say experts

Coronavirus outbreak cripples all major sectors in country; sharp fall in revenues, unemployment to rise in coming days
Business

Coronavirus outbreak cripples all major sectors in country; sharp fall in revenues, unemployment to rise in coming days

The coronavirus outbreak happened to be a major setback for hopes of a revival in beleaguered auto sector of the country, which had grappled in the red zone due to sharp fall in demand for over two quarters.

Yes Bank to be dropped from Nifty 50 from 19 March instead of 27 March: NSE
Business

Yes Bank to be dropped from Nifty 50 from 19 March instead of 27 March: NSE

NSE Indices' Index Maintenance Sub-Committee has decided to make the replacement of stocks in various indices as part of its periodic review. These changes would become effective from March 27, 2020.

UBS cuts India GDP growth forecast to 5.1% for FY21 on fears around coronavirus outbreak, weak domestic credit growth
Business

UBS cuts India GDP growth forecast to 5.1% for FY21 on fears around coronavirus outbreak, weak domestic credit growth

The GDP growth is set to slip to a decadal low of 5 percent for FY20 as per official estimates and hopes of a revival are being pinned on the next fiscal